Phase 4 N=711 RAPID EC - Rct Assessing Pregnancy With Intrauterine Devices for EC
Contraception
Primary: Percentage of Participants Reporting a Pregnancy — 0; 0.3 % of participants reporting pregnancy
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=83 Safety, Tolerability and Efficacy of Nidufexor in Patients With Diabetic Nephropathy
Diabetic Nephropathy
Primary: Ratio to Baseline in Urinary Albumin to Creatinine Ratio (UACR) — 0.90; 1.06; 0.83; 1.00 Ratio to baseline
Phase 2 N=30 Modulation of GABA-A Receptors in Parkinson Disease-Flumazenil Arm
Parkinson Disease
Primary: Postural Instability and Gait Disorder (PIGD) Score — 4.625; 4.625; 4.23; 4.09 score on a scale — p=0.0407
Phase 2 N=25 Evaluate SAGE-547 in Participants With Essential Tremor
Essential Tremor
Primary: Stage 1: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 12.0; 20.0; 0; 0 percentage of participants
N/A N=38 Reducing the Experience of Menopausal Symptoms Through Temperature
Hot Flashes · Menopause
Primary: Hot Flash Diary — 9 number of hot flashes per week
N/A N=352 Community Intervention to Reduce Tobacco Use in Pregnant Women
Nicotine Dependence
Primary: Number of Participants With Tobacco Abstinence at 6-months Post-partum — 161; 135 Participants — p=0.38
N/A N=38 Assessing Effects of a Denture Gel on Gum Abrasions
Gum Injury
Primary: Abrasion Assessment (Number) — 3.65; 4.11 number of abrasions
Phase 2 N=462 Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis
Moderate to Severe Atopic Dermatitis
Primary: Percent Change From Baseline in Eczema Area and Severity Index (EASI) Clinical Score at Week 16 — -57.589; -56.734; -38.099; -42.142 percentage change — p== 0.008
Phase 2 N=72 A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)
B-Cell Malignancies
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 1; 3; 3; 32 Participants
Phase 2 N=72 A Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Participants Infected With Respiratory Syncytial Virus
Respiratory Syncytial Virus Infections
Primary: Area Under the Respiratory Syncytial Virus (RSV) Viral Load (VL)-Time Curve (AUC) From Immediately Prior to First Dose of Study Drug (Baseline) Through Day 3 — 207.3…
N/A N=92 MRI Assessing Clinical Usability of STrategically Acquired Gradient Echo on Human Participants
MRI
Primary: Numeric Rating Scale of Clinical Usability Assessment of STAGE Outputs — 49; 40; 0; 0 Participants
Phase 3 N=38 Hyperpolarized Xenon MRI for Assessment of Pulmonary Function in Lung Resection
Pulmonary Surgical Procedures
Primary: Predicted Percentage of Remaining Pulmonary Function — 73.4; 71.9 percentage of remaining function
Phase 3 N=1,010 Adaptive COVID-19 Treatment Trial 4 (ACTT-4)
COVID-19
Primary: The Proportion of Participants Not Meeting Criteria for One of the Following Two Ordinal Scale Categories at Any Time: 8) Death; 7) Hospitalized, on Invasive Mechanical…
N/A N=180 Evaluation of Effectiveness and Safety of Radiesse (+) to Improve the Contour of Jawline by Adding Volume to the Jawline
Improvement of Jawline Contour
Primary: Responder Rate According to the Merz Jawline Assessment Scale (MJAS) — 75.6; 8.8 percentage of participants — p=<0.0001
Phase 2 N=35 Neuroimaging Reward, Behavioral Treatment, and Smoking Cessation
Smoking
Primary: Change in BOLD (Blood-oxygen-level-dependent) Response to Monetary Reward — -0.085; -0.067 fMRI BOLD signal — p=0.891